全球局灶节段性肾小球硬化症药物市场 – 行业趋势和 2030 年预测

局灶节段性肾小球硬化症药物市场分析及规模

局灶节段性肾小球硬化的发病率与其他肾小球疾病相比相对较高。目前，FDA 尚未批准局灶节段性肾小球硬化的治疗方法。美国局灶节段性肾小球硬化药物的治疗市场规模主要占非说明书治疗方案，例如非免疫疗法和免疫疗法。COVID-19 也对市场增长产生了重大影响。

Data Bridge Market Research 分析了 2023-2030 年预测期内全球局灶节段性肾小球硬化药物市场的增长率。在上述预测期内，全球局灶节段性肾小球硬化药物市场的预期复合年增长率趋于 8.20% 左右。2022 年市场价值为 126 亿美元，到 2030 年将增长到 237 亿美元。除了市场价值、增长率、细分市场、地理覆盖范围、市场参与者和市场情景等市场洞察外，Data Bridge Market Research 团队策划的市场报告还包括深入的专家分析、患者流行病学、管道分析、定价分析和监管框架。

局灶节段性肾小球硬化症药物市场范围和细分

Market Definition

Focal segmental glomerulosclerosis is a kind of renal disorder affecting the small filtering unit of kidneys called glomeruli that involves kidney scarring. It is caused by multiple factors, such as autoimmune disorders, genetic factors, infection in other body parts, and sclerotic diseases. It is a rare disease affecting kidney function by damaging and attacking the glomeruli. Kidney defects typically characterize this disease by obesity, obstructive sleep apnea, birth, sickle cell anemia, and viruses such as HIV.

Global Focal Segmental Glomerulosclerosis Drugs Market Dynamics

Drivers

• Increased Prevalence of Focal segmental glomerulosclerosis

Focal segmental glomerulosclerosis (FSGS), a rare health condition, affects around 210,200 patients worldwide, and about 14,000 to 16,000 new cases are diagnosed annually. The increasing numbers and the considerable opportunities are boosting the market's growth.

• Growing Elderly Population

Life expectancy is increasing all over the globe, which has led to an increase in the elderly population. This trend positively impacts the industry by increasing the occurrence of the disease and creating per capita demand for its remedies. A rise in elderly visits to outpatient facilities and ambulatory surgery centers (ASC) has been witnessed, resulting in the sound growth of the global focal segmental glomerulosclerosis drugs market during the forecast period. Thus, it creates more opportunities for market growth.

Opportunities

• Higher Therapeutic Options

The latest therapy for primary focal segmental glomerular sclerosis includes immunosuppressive agents, such as glucocorticoids and calcineurin inhibitors. Moreover, steroid therapy is among the most basic and standard treatments with oral prednisone. Some of the main developing companies that have their potential drug candidates in the pipeline are Chemocentryx, Pharmaceuticals, Retrophin Inc., Reata, and Vertex Pharmaceuticals. This boosts market growth.

• Increased Clinical Research Activities

Increasing R&D for focal segmental glomerulosclerosis drugs by several key manufacturers is also fuelling the growth of the focal segmental glomerulosclerosis drugs market. For instance, Pfizer Inc. is going through a clinical trial to evaluate its drug, PF-06730512, in adults with primary focal segmental glomerulosclerosis. This drug is currently in Phase II study and is expected to complete in June 2021. Thus, all these research activities create many market growth opportunities.

 Restraints/Challenges

• Lack of Medical Care

The lack of medical care in undeveloped economies may restrain the growth of the focal segmental glomerulosclerosis drugs market during the forecast period. Not much awareness can lead to the unavailability of treatment and limit market growth.

• High Cost

The huge expenditure associated with drug therapy, dialysis, and kidney transplant hamper the market growth. The huge drug development and the related processes are hindering the growth of the market.

This global focal segmental glomerulosclerosis drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global focal segmental glomerulosclerosis drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth

COVID-19 Impact on Global Focal Segmental Glomerulosclerosis Drugs Market

The global focal segmental glomerulosclerosis drugs market growth has been significantly impacted because of COVID-19 worldwide. The huge severity of the COVID-19 pandemic and its following outbreaks have led policymakers, regulators, market players, and even the general population to come forward and fight against the crisis. The collaborations and engagements across the value chain have thus paved the way to numerous latest healthcare models, business and operating models for the economy, and new ways of working.

Global Focal Segmental Glomerulosclerosis Drugs Market Scope

The global focal segmental glomerulosclerosis drugs market is segmented on the basis of treatment, route of administration, distribution channel, and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

• Corticosteroids
• Immunosuppressive Drugs
• ACE inhibitors
• A.R. Blockers
• Diuretics
• Others

Route of Administration

• Oral
• Parenteral

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Focal Segmental Glomerulosclerosis Drugs Market Regional Analysis/Insights

The global focal segmental glomerulosclerosis drugs market is analysed and market size insights and trends are provided by treatment, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global focal segmental glomerulosclerosis drugs market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific has been witnessing positive growth for the global focal segmental glomerulosclerosis drugs market throughout the forecasted period due to growing initiatives taken by the government and pharmaceutical organizations to spread awareness and the presence of generic manufacturers.

North America dominates the market due to the advancement of technology for focal segmental glomerulosclerosis drugs and increasing initiatives several pharmaceutical organizations take to generate novel formulations.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Focal Segmental Glomerulosclerosis Drugs Market Share Analysis

The global focal segmental glomerulosclerosis drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global focal segmental glomerulosclerosis drugs market.

Key players operating in the global focal segmental glomerulosclerosis drugs market include:

• Pfizer Inc (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Mylan N.V. (U.S.)
•  Fresenius Kabi AG (Germany)
•  Hikma Pharmaceuticals PLC (Japan)
• Novartis AG (Switzerland)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Bristol Myers Squibb Company (U.S.)
• 葛兰素史克公司 (美国)
• 拜耳公司（德国）
• 太阳制药工业有限公司 (印度)
•  Accord Healthcare（英国）
• Wockhardt（印度）
• Alkem Labs（印度）
• 大塚制药株式会社（日本）

研究方法：局灶节段性肾小球硬化症药物市场

数据收集和基准年分析是使用具有大样本量的数据收集模块进行的。市场数据使用市场统计和连贯模型进行分析和估计。市场份额分析和关键趋势分析也是市场报告中的主要成功因素。如需了解更多信息，请请求分析师致电或下拉询问。

DBMR 研究团队使用的关键研究方法是数据三角测量，涉及数据挖掘、数据变量对市场影响的分析以及主要（行业专家）验证。除此之外，数据模型还包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。

可定制

Data Bridge Market Research 是高级形成性研究领域的领导者。我们很自豪能够为现有和新客户提供符合其目标的数据和分析。报告可以定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（Factbook）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。

SKU-55650